Tissue platinum concentrations linked to response in NSCLC

August 14, 2012
Tissue platinum concentrations linked to response in NSCLC
For patients with non-small-cell lung cancer who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published online Aug. 13 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published online Aug. 13 in the Journal of Clinical Oncology.

Eric S. Kim, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues used flameless atomic absorption spectrophotometry to measure total platinum concentrations in 44 archived fresh-frozen specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. The effect of tissue platinum concentration on response and survival was examined.

The researchers observed a significant association between tissue platinum concentration and percent reduction in . This association was also seen with cisplatin, carboplatin, and all histology subgroups. Variables such as the number of cycles and time lapse from last chemotherapy had no significant impact on platinum concentration. Time to recurrence, progression-free survival, and overall survival were significantly longer in patients with higher platinum concentration, after adjustment for the number of cycles.

"Our data strongly support reduced drug accumulation as a significant mechanism of platinum resistance," the authors write. "Enhanced understanding of the molecular mechanism of platinum accumulation by will be necessary to identify surrogate biomarkers for platinum accumulation that could be developed prospectively for individualizing therapy."

Explore further: Chemotherapy's effect on overall survival seems to increase based on tumor size

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Chemotherapy's effect on overall survival seems to increase based on tumor size

May 15, 2012
The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node ...

DNA repair pathway score for predicting chemotherapy response in ovarian cancer patients

April 13, 2012
A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of ...

Drug cocktail boosts ovarian cancer survival time

June 2, 2012
A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

Recommended for you

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.